ClinicalTrials.gg
RecruitingNCT06514677Updated Mar 12, 2025

Non-Surgical Treatment of Peri-Implantitis With Ultrasonic Carbon Tip

An interventional study of Ultrasonic Carbon Tip and Titanium Curette in Peri-Implantitis and Alveolar Bone Loss, sponsored by Kutahya Health Sciences University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Kutahya Health Sciences University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.

Planned enrollment
8th of 26
60 · median 50
Started
2023
with 8 others
No phase
26 of 55
10 open now
Primary completion
2025-05
later than 2 of 18 live
Registered
21st of 55
by date
Lead sponsor
4 of 55
Kutahya Health Sciences University

Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is one of 9 that started in 2023, is one of 26 with no phase, reaches primary completion later than 2 of the 18 other live ones, and was the 21st registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

As the frequency of dental implants increases, the incidence of complications and peri-implant diseases also increases. Early diagnosis and treatment of the disease is important to prevent consequences up to implant loss. Non-surgical treatment is the recommended treatment in the first stage due to its shorter duration and low morbidity rate. Non-surgical treatment of peri-implantitis provides clinical improvements such as reduced bleeding on probing (20-50%) and, in some cases, reduced pocket depth (≤ 1 mm). This study aims to clinically and radiographically compare two different mechanical treatments in patients with mild and moderate peri-implantitis.

Read the detailed description

60 patients with at least one implant with mild to moderate peri-implantitis, defined as 2-4 mm radiographic reduced bone level, bleeding index (BI) ≥ 2, and probing pocket depth (PPD) ≥ 4 mm will be randomly allocated to test and control groups, receiving titanium curettes or ultrasonic Carbon tips debridement, respectively. Treatment was performed at baseline. Plaque index (PI), gingival index (GI), Periodontal pocket depth (PD), Bleeding on probing (BOP) gingival recession (GR) and Clinical attachment level (CAL) will be measured at four sites per implant and recorded by examiner at baseline, one, three, six and twelve months. Pus will be recorded as present/not present. The radiographic marginal bone level changes will be calculated at baseline, third months, sixth months and 12 months.

03

Conditions studied

  • Peri-Implantitis
  • Alveolar Bone Loss
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (≥18 years old)
  2. Systemically healthy ( 1 and ASA class 2)
  3. Full-mouth plaque scores ≤20%
  4. Implant had been in function for more than 6 months
  5. Absence of plaque around the implant
  6. Consent to complete all follow-up visits

Exclusion criteria

Exclusion criteria:

  1. Mobile implant
  2. Overhanging restorations that prevent access to the implant for clinical measurements
  3. Unresolvable technical complications that can cause peri-implantitis
  4. Presence of active periodontal disease
  5. Implants with a history of peri-implantitis treated using graft materials
  6. Use of drugs that cause gingival hyperplasia
  7. Systemic antibiotic use in the last 3 months
  8. Acute and chronic medical conditions that prevent the patient from participating in the study
  9. Presence of uncontrolled severe peri-implantitis from neighbouring implants
  10. History of radiotherapy in the head and neck region
  11. Receiving acute chemotherapy
  12. Current therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Ultrasonic Carbon

    Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment

    Procedure: Ultrasonic Carbon Tip

  • Active comparator
    Titanium

    Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment

    Procedure: Titanium Curette

Interventions

  • ProcedureUltrasonic Carbon Tip

    Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment

  • ProcedureTitanium Curette

    Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment

06

What researchers measure

Primary outcomes

  1. Periodontal depth decrease

    Periodontal pocket depth (PD) decreasing baseline to 12th month

    Time frame: Baseline to 12th month

Secondary outcomes

  1. marginal bone level changes

    Marginal bone level changes will be calculated at standardized periapical radiography

    Time frame: Baseline to 12th month

07

Study locations

1 of 1 sites recruiting
  • Kütahya Health Sciences University Faculty of Dentistry, Department of Periodontology
    Kütahya, 43100, Turkey
    Recruiting
    • Berceste Güler · Contact
08

References and documents

Publications

  • Linares A, Sanz-Sanchez I, Dopico J, Molina A, Blanco J, Montero E. Efficacy of adjunctive measures in the non-surgical treatment of peri-implantitis: A systematic review. J Clin Periodontol. 2023 Jun;50 Suppl 26:224-243. doi: 10.1111/jcpe.13821. Epub 2023 May 4. PubMed 37143407 ↗
  • Blasi A, Iorio-Siciliano V, Pacenza C, Pomingi F, Matarasso S, Rasperini G. Biofilm removal from implants supported restoration using different instruments: a 6-month comparative multicenter clinical study. Clin Oral Implants Res. 2016 Feb;27(2):e68-73. doi: 10.1111/clr.12530. Epub 2014 Dec 11. PubMed 25496020 ↗
  • Mensi M, Viviani L, Agosti R, Scotti E, Garzetti G, Calza S. Comparison between four different implant surface debridement methods: an in-vitro experimental study. Minerva Stomatol. 2020 Oct;69(5):286-294. doi: 10.23736/S0026-4970.20.04342-3. PubMed 33174712 ↗
  • Nart J, Pons R, Valles C, Esmatges A, Sanz-Martin I, Monje A. Non-surgical therapeutic outcomes of peri-implantitis: 12-month results. Clin Oral Investig. 2020 Feb;24(2):675-682. doi: 10.1007/s00784-019-02943-8. Epub 2019 May 23. PubMed 31123873 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2025, 17 months after the start.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 17 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 23, 2024
StartActual
Dec 1, 2023
Primary completionEst.
May 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514677
Responsible party
Berceste Guler (Assoc Prof, Kutahya Health Sciences University) — Principal investigator
First posted
Jul 23, 2024
Start date
Dec 1, 2023
Primary completion
May 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Mar 12, 2025

Study contacts

Berceste Guler Ayyildiz, d
Contact
berceste.guler@ksbu.edu.tr
+90 (274) 260 00 43

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion